Apr 12, 2019 — Pharmaceutical development company with three new drug products in the fourth year of development. One of the drugs is a new antibiotic for use with cattle and pigs, and the FDA is expected to approve the drug for distribution in 2021. The other two drugs are for human use, one for pain (non-opioid) and nausea in advanced cancer patients, and the other for diabetic patients. These drugs should be eligible for Orphan Drug status and Pediatric Exclusivity, giving them 7.5 years of exclusivity free of generic competition. The FDA is expected to approve these drugs in 2026.
Although the company will not have revenues until 2021, the veterinary antibiotic is expected to generate almost $50 Million in 2022, and revenues in excess of $120 Million for all three drugs are projected by 2026. All three pipeline drugs have huge markets and will generate substantial returns.
The company is currently seeking an equity partner to invest $18 Million for a 30% ownership stake. The proceeds will be used for clinical testing and approval processes for the three pipeline drugs, and $3 Million will be available for distribution to current stakeholders.